14521-98-3

Basic information

• Product Name: (1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine
• Synonyms: (1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine
• CAS NO: 14521-98-3
• Molecular Formula: C₃₀H₃₅NO₄
• Molecular Weight: 473.6032
• Mol File: 14521-98-3.mol
• Article Data: 1

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.32g/cm³
• Refractive Index: 1.679
• CAS DataBase Reference: (1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine(CAS DataBase Reference)
• NIST Chemistry Reference: (1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine(14521-98-3)
• EPA Substance Registry System: (1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine(14521-98-3)

Safety Data

• Hazardous Substances Data: 14521-98-3(Hazardous Substances Data)

Usage

General Description

(1-hydroxy-1-methyl-3-phenylpropyl)-6,14-endo-ethenotetrahydrooripavine, also known as hydrocodone, is a semi-synthetic opioid derived from codeine. It is commonly used as a prescription pain medication and cough suppressant. Hydrocodone works by binding to opioid receptors in the brain and spinal cord, which can result in pain relief and a sense of euphoria. However, it also has addictive properties and can lead to physical dependence and withdrawal symptoms when discontinued. Due to its potential for abuse and overdose, hydrocodone is classified as a Schedule II controlled substance in the United States, meaning it has a high potential for abuse and is only available through a prescription from a qualified healthcare provider.

InChI:InChI=1/C30H35NO4/c1-27(33,12-11-19-7-5-4-6-8-19)22-18-28-13-14-30(22,34-3)26-29(28)15-16-31(2)23(28)17-20-9-10-21(32)25(35-26)24(20)29/h4-10,13-14,22-23,26,32-33H,11-12,15-18H2,1-3H3/t22-,23-,26-,27-,28-,29+,30-/m1/s1

Upstream product

• 13965-63-4 (20R)-(5α,7α)-4,5-epoxy-3,6-dimethoxy-α,17-dimethyl-α-(2-phenylethyl)-6,14-ethenomorphinan-7-methanol 
• 13965-63-4 (R)-2-(4,5α-epoxy-3,6-dimethoxy-17-methyl-6α,14α-etheno-morphinan-7α-yl)-4-phenyl-butan-2-ol 

Downstream Products

• 26627-00-9 (R)-2-(4,5α-epoxy-6-methoxy-17-methyl-8α,14α-etheno-morphinan-7α-yl)-4-phenyl-butan-2-ol 
• 1187551-67-2 6-O-desmethyl phenethyl-orvinol 
• 1613512-03-0 6-O-(2-fluoroethyl)phenethyl-orvinol 
• 1613512-00-7 6-O-(2-fluoroethyl)-3-O-trityl-6-O-desmethyl phenethyl-orvinol 
• 1187551-69-4 3-O-trityl-6-O-desmethyl phenethyl-orvinol 

Relevant articles and documents

Synthesis and evaluation of a full-agonist orvinol for PET-imaging of opioid receptors: [11C]PEO

Antagonist radiotracers have shown only a low sensitivity for detecting competition from high-efficacy agonists at opioid receptors (ORs) in vivo. We report that [11C]PEO binds with high affinity to μ and κ-opioid receptors, is a full agonist, and concentrates in brain regions of rats with a high density of the μ-OR after intravenous injection. Blocking studies with μ and κ-OR selective compounds demonstrated that the binding of [11C]PEO is saturable and selective to the μ-OR in rat brain.